Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure

AIMS: Explore the efficacy, safety and tolerability of the dual sodium–glucose cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type‐2 diabetes mellitus (T2DM) and heart failure. METHODS: This multicentre, parallel‐group phase IIA study randomized 125 patients with T2DM and hea...

Descripción completa

Detalles Bibliográficos
Autores principales: de Boer, Rudolf A., Núñez, Julio, Kozlovski, Plamen, Wang, Yi, Proot, Pieter, Keefe, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318993/
https://www.ncbi.nlm.nih.gov/pubmed/32068914
http://dx.doi.org/10.1111/bcp.14248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318993/
https://www.ncbi.nlm.nih.gov/pubmed/32068914
http://dx.doi.org/10.1111/bcp.14248

Ejemplares similares